Nucana ( (NCNA) ) has shared an update.
NuCana announced its financial results for the year ending December 31, 2024, and provided updates on its clinical programs. The company shared promising data from its lead anti-cancer medicines, NUC-7738 and NUC-3373, highlighting significant tumor reductions and prolonged progression-free survival in patients with melanoma and advanced solid tumors. NuCana plans to expand its study of NUC-7738 in 2025 and engage with the FDA for regulatory guidance. Despite a reduction in cash reserves, NuCana’s financial position remains stable, with sufficient funds to support operations into Q3 2025.
More about Nucana
NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes by utilizing ProTide technology to enhance the effectiveness and safety of chemotherapy agents. Their pipeline includes NUC-3373 and NUC-7738, which are being evaluated for their potential to overcome the limitations of conventional nucleoside analogs.
YTD Price Performance: -31.94%
Average Trading Volume: 112,237
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.38M
Learn more about NCNA stock on TipRanks’ Stock Analysis page.